A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Mar 18, 2013

Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, March 18, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its own...

Read more about Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Mar 13, 2013

Astellas Pharma Inc.: Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

Read more about Astellas Pharma Inc.: Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan
Mar 12, 2013

Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors

Read more about Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Mar 11, 2013

Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374

Read more about Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374
Mar 7, 2013

Astellas and UCB Launch Cimzia® (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis

Tokyo, Japan, 7 March, 2013 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB Japan (“UCB Japan”: Tokyo, Japan, President and Representative...

Read more about Astellas and UCB Launch Cimzia® (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis
Feb 28, 2013

Astellas Voluntarily Adopts International Financial Reporting Standards (IFRS)

Read more about Astellas Voluntarily Adopts International Financial Reporting Standards (IFRS)
Feb 26, 2013

NEW CLASS OF TREATMENT NOW AVAILABLE FOR PATIENTS WITH OVERACTIVE BLADDER

Read more about NEW CLASS OF TREATMENT NOW AVAILABLE FOR PATIENTS WITH OVERACTIVE BLADDER
Feb 21, 2013

Pasetocin® and Sawacillin® : Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole

Read more about Pasetocin® and Sawacillin® : Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
Feb 20, 2013

Astellas Submits Additional Indication Application for Hypnosedative, Dormicum® in Japan

Read more about Astellas Submits Additional Indication Application for Hypnosedative, Dormicum® in Japan
Feb 13, 2013

Enzalutamide Data Presented at ASCO GU Symposium

-- Six Abstracts Presented Include Data from Phase II Study Investigating XTANDI® (enzalutamide) Capsules in Hormone-Naïve Prostate Cancer --

Read more about Enzalutamide Data Presented at ASCO GU Symposium

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts